[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Sarepta Therapeutics
Sarepta Therapeutics announced the refinancing of approximately $XXX million of convertible senior notes due 2027, enhancing financial flexibility. The company also granted a $XX million equity award to CEO Douglas Ingram.
About Sarepta Therapeutics
Sarepta Therapeutics is a biotechnology company focused on gene therapies for rare diseases.
Insights
- sarepta therapeutics sentiment is up XXXXX% from the previous week.
- sarepta therapeutics creators is up XXXXXX% from the previous week.
- sarepta therapeutics engagements is up XXXXXX% from the previous week.
- sarepta therapeutics mentions is up XXXXXX% from the previous week.
- sarepta therapeutics posts created is up XXX% from the previous week.
Engagements: XXXXX (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XXXXXX
X Week: XXXXX +270%
X Month: XXXXXX +14%
X Months: XXXXXXXXX +659%
X Year: XXXXXXXXX +442%
1-Year High: XXXXXXX on 2025-08-05
1-Year Low: X on 2025-11-08
Engagements by network (24h): News: XX Reddit: XXX X: XXXXX YouTube: XX
Mentions: XX (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XX
X Week: XXX +135%
X Month: XXX -XX%
X Months: XXXXX +118%
X Year: XXXXX +159%
1-Year High: XXX on 2025-07-18
1-Year Low: X on 2025-11-04
Mentions by network (24h): News: X Reddit: XX X: XXX YouTube: X
Creators: XX (24h)
Creators 24-Hour Time-Series Raw Data
XX unique social accounts have posts mentioning Sarepta Therapeutics in the last XX hours which is down XX% from XX in the previous XX hours
Daily Average: XX
X Week: XX +113%
X Month: XXX -XX%
X Months: XXX +133%
X Year: XXXXX +176%
1-Year High: XXX on 2025-07-18
1-Year Low: X on 2025-01-26
The most influential creators that mention Sarepta Therapeutics in the last XX hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @Investingcom | X | XXXXXXXXX | X | XX |
| @Capital_Letterhead49 | X | X | XX |
Sentiment: XX%
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
X Week: XXX% +22%
X Month: XXX% no change
X Months: XXX% +18%
X Year: XXX% no change
1-Year High: XXX% on 2024-12-13
1-Year Low: XX% on 2025-03-18
Most Supportive Themes:
- Scholarship Program Announcement: (30%) Sarepta Therapeutics announced recipients of the Route XX Duchenne Scholarship Program for 2025-2026.
Most Critical Themes:
- Duchenne Trial Failure: (30%) Sarepta's late-stage Duchenne trial for AMONDYS XX and VYONDYS XX failed to meet its primary endpoint.
- Elevidys Challenges and Restructuring: (25%) Sarepta Therapeutics is facing challenges with its Elevidys drug, leading to restructuring.
- Safety Concerns and Investigations: (15%) There are investigations into the safety of Sarepta's Elevidys drug.
Top Sarepta Therapeutics News
Top news links shared on social in the last XX hours
Showing a maximum of X news posts for non-authenticated requests. Use your API key in requests for full results.
"Sarepta Therapeutics grants $XX million equity award to CEO Douglas Ingram By Investing.com"
News Link @Investingcom 2025-12-10T22:20Z 1.4M followers, XXX engagements
"Wedbush initiates Sarepta Therapeutics stock coverage with Outperform rating By Investing.com"
News Link @Investingcom 2025-12-10T00:32Z 1.4M followers, XXX engagements
Top Sarepta Therapeutics Social Posts
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"After a challenging year for Sarepta Therapeutics its chief executive has received his first equity grant in about eight years"
X Link @BosBizJournal 2025-12-12T11:20Z 73.6K followers, XXX engagements
"Sarepta Therapeutics Announces Refinancing of Approximately $XXX Million of XXXX% Convertible Senior Notes due 2027 $SRPT #StockMarket"
X Link @Paula_Stout_ 2025-12-12T07:03Z XX followers, XXX engagements
"Sarepta Therapeutics announces refinancing of $XXX million convertible senior notes enhancing financial flexibility for future growth. $SRPT #FinanceNews 📈"
X Link @notdumbmoney 2025-12-11T16:02Z XXX followers, XXX engagements
"$SRPT is Sarepta Therapeutics a biopharma company focused on genetic medicines for rare diseases like Duchenne muscular dystrophy. Business outlook: Recently refinanced $291M debt to 2030 showing bondholder confidence. Stock gapped up to $XX amid FDA clearances. Analysts mixed: Wedbush Outperform ($32 target) consensus Hold ($34 target). Q3 revenue beat estimates ($399M) but EPS missed (-$0.13). Projections: $1.4B revenue by 2028 though with declining growth negative cash flow and competition risks"
X Link @grok 2025-12-11T15:20Z 6.8M followers, XXX engagements